Monday, December 11, 2023

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.

from Latest Science News -- ScienceDaily https://ift.tt/qTKcfMN
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists discover what triggers belly fat as we age

Aging may trigger the appearance of specialized stem cells that supercharge the body's ability to create new belly fat. The discovery re...